Related Experiment Video
Updated: Jun 7, 2025
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation
Emilie J Lambourg1, Edouard L Fu2, Stuart McGurnaghan3
1Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee.
Rationale & Objective:
Despite a lack of supporting evidence, current guidance recommends against the use of metformin in people with advanced kidney impairment. This observational study compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after developing stage 4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR]<30mL/min/1.73m2).
Study Design:
Nationwide observational cohort study.
Setting & Participants:
All adults with type 2 diabetes and incident stage 4 CKD in Scotland who were treated with metformin between January 2010 and April 2019.
Exposure:
Stopping versus continuing metformin within 6 months following incident stage 4 CKD.
Outcome:
Primary outcome was all-cause mortality. Secondary outcomes included major adverse cardiovascular events (MACE).
Analytical Approach:
Target trial emulation with clone-censor-weight design and marginal structural models fit for sensitivity analyses.
Results:
In a population of 371,742 Scottish residents with a diagnosis of type 2 diabetes before April 30, 2019, 4,278 were identified as prevalent metformin users with incident CKD stage 4. Within 6 months of developing CKD stage IV, 1,713 (40.1%) individuals discontinued metformin. Compared with continuing metformin, stopping metformin was associated with a lower 3-year survival (63.7% [95% CI, 60.9-66.6] vs 70.5% [95% CI, 68.0-73.0]; HR, 1.26 [95% CI, 1.10-1.44]), and the incidence of MACE was similar between both strategies (HR, 1.05 [95% CI, 0.88-1.26]). Marginal structural models confirmed the higher risk of all-cause mortality and similar risk of MACE in patients who stopped versus continued metformin (all-cause mortality: HR, 1.34 [95% CI, 1.08-1.67]; MACE: HR, 1.04 [95% CI, 0.81-1.33]).
Limitations:
Residual confounding.
Conclusions:
The continued use of metformin may be appropriate when eGFR falls below 30mL/min/1.73m2. Randomized controlled trials are needed to confirm these findings.
Plain-Language Summary:
Current guidance recommends against the use of metformin in people with advanced kidney impairment despite a lack of evidence. It is therefore currently unclear how the decision to stop versus continue metformin in patients who reach stage 4 CKD impacts their risk of mortality and cardiovascular events. This study showed that stopping metformin after reaching stage 4 CKD was associated with reduced survival that did not appear to be mediated by an increase in adverse cardiovascular outcomes. These findings may support the continued use of metformin in patients with advanced kidney impairment, but further research is needed to confirm these observations.
Insights
Stopping metformin in patients with advanced kidney disease (CKD) was linked to reduced survival. This observational study suggests continued metformin use may be appropriate for type 2 diabetes patients with stage 4 CKD.
Area of Science:
- Nephrology
- Endocrinology
- Clinical Pharmacy
Background:
- Current guidelines often advise against metformin use in advanced kidney impairment, despite limited evidence.
- The impact of continuing or stopping metformin in type 2 diabetes patients with stage 4 chronic kidney disease (CKD) on mortality and cardiovascular events is unclear.
Purpose of the Study:
- To compare outcomes of patients with type 2 diabetes who continued versus stopped metformin after developing stage 4 CKD (eGFR <30mL/min/1.73m2).
Main Methods:
- Nationwide observational cohort study of adults with type 2 diabetes and incident stage 4 CKD in Scotland (2010-2019).
- Target trial emulation using clone-censor-weight design and marginal structural models.
- Primary outcome: all-cause mortality. Secondary outcome: major adverse cardiovascular events (MACE).
Main Results:
- Analysis included 4,278 patients; 40.1% discontinued metformin within 6 months of stage 4 CKD diagnosis.
- Stopping metformin was associated with lower 3-year survival (HR, 1.26; 95% CI, 1.10-1.44).
- Marginal structural models confirmed higher all-cause mortality risk (HR, 1.34; 95% CI, 1.08-1.67) and similar MACE risk (HR, 1.04; 95% CI, 0.81-1.33) for those who stopped metformin.
Conclusions:
- Continued metformin use may be appropriate for patients with stage 4 CKD (eGFR <30mL/min/1.73m2).
- Stopping metformin was associated with reduced survival, not explained by increased cardiovascular events.
- Randomized controlled trials are necessary to confirm these findings.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
01:23Dipeptidyl Peptidase 4 Inhibitors
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:15Diabetes: Symptoms, Diagnosis, and Complications